Table 1.
Baseline Characteristics of Study Population
| Characteristic | Study POT-CP043014 (n = 13) | Study POT-CP121614 (n = 164) | Study APL2-203 (n = 17) | Study APL2-303 (n = 67) | Total (n = 261) |
|---|---|---|---|---|---|
| Age, mean (SD), yrs | 74.5 (8.02) | 80.3 (7.55) | 77.2 (8.76) | 79.3 (7.32) | 79.6 (7.69) |
| Disease type, n (%) | |||||
| GA | 0 (0) | 164 (100) | 0 (0) | 67 (100) | 231 (88.5) |
| nAMD | 13 (100) | 0 (0) | 17 (100) | 0 (0) | 30 (11.5) |
| Sex, n (%) | |||||
| Male | 5 (38.5) | 60 (36.6) | 10 (58.8) | 38 (56.7) | 113 (43.3) |
| Female | 8 (61.5) | 104 (63.4) | 7 (41.2) | 29 (43.3) | 148 (56.7) |
| Race, n (%) | |||||
| White | 13 (100) | 159 (97.0) | 16 (94.1) | 66 (98.5) | 254 (97.3) |
| Black | 0 (0) | 2 (1.2) | 0 (0) | 0 (0) | 2 (0.8) |
| Other or missing | 0 (0) | 3 (1.8) | 1 (5.9) | 1 (1.5) | 5 (1.9) |
| Renal impairment | |||||
| Normal | 4 (30.8) | 37 (22.6) | 4 (23.5) | 6 (9.0) | 51 (19.5) |
| Mild | 7 (53.8) | 70 (42.7) | 9 (52.9) | 26 (38.8) | 112 (42.9) |
| Moderate | 2 (15.4) | 45 (27.4) | 3 (17.6) | 31 (46.3) | 81 (31.0) |
| Severe | 0 (0) | 2 (1.2) | 0 (0) | 0 (0) | 2 (0.8) |
| End stage | 0 (0) | 6 (3.7) | 1 (5.9) | 4 (6.0) | 11 (4.2) |
| C3, mean (SD), g/L | 1.52 (0.261) | 1.23 (0.211) | 0 (0) | 1.02 (0.200) | 1.20 (0.241) |
GA = geographic atrophy; nAMD = neovascular age-related macular degeneration; SD = standard deviation.